Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease

by GlobeNewswire

Oakville1
Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ET Read More

Categories

Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%
Romanian Inflation Ends Tumultuous Year in Politics Close to 10%
UK Boosts Support For Offshore Wind in Bumper Auction
UK Boosts Support For Offshore Wind in Bumper Auction
Ireland Is Trying to Get Back on the Data Center Bandwagon
Ireland Is Trying to Get Back on the Data Center Bandwagon
Notice Concerning Change of Representative Executive Officer
Notice Concerning Change of Representative Executive Officer
Polish Recycler Bets Millions on Europe’s Critical Metals Push
Polish Recycler Bets Millions on Europe’s Critical Metals Push
Blistering Metals Rally Sends Silver, Tin and Copper to Records
Blistering Metals Rally Sends Silver, Tin and Copper to Records
Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities
Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities
TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale
TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale
New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS
New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS
TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics
TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics

Share on Social Media

Grace Cabral
Grace Cabral

REALTOR® | License ID: 9541137

+1(416) 278-2809 | grace@gracecabral.com

GET MORE INFORMATION

Name
Phone*
Message

By checking this box, I agree by electronic signature to the Electronic Disclosure Consent Agreement; to receive recurring marketing communication from or on behalf of Real Broker Ontario Ltd., including auto-dialed calls, texts, and artificial/prerecorded voice messages (message frequency varies; data rates may apply; reply "STOP" to opt-out of texts or "HELP" for assistance); and to the Terms of Service and Privacy Policy of this website. Consent not required to make a purchase. I understand that I can call to obtain direct assistance.